CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancer…
$0.86-2.39%
报价 2026-11-06
市值
$10.2M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -56.6%
$0.72$1.98
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| GDTCCytoMed Therapeutics Limited | $10.2M | -2.4% | – | -20.5% | – | – | – | |
| PTNPalatin Technologies, Inc. | $11.2M | +9.8% | +104.6% | 99.8% | – | – | – | |
| HINDVyome Holdings, Inc. | $11.1M | -3.1% | +50.0% | 9% | – | – | – | |
| CURXCuranex Pharmaceuticals Inc Common Stock | $9.7M | +7.4% | – | 0% | – | – | – | |
| DAREDaré Bioscience, Inc. | $9.6M | +2.4% | -62.5% | 30,089.1% | – | – | – | |
| MTVAMetaVia Inc. | $9.4M | +31.2% | -100.0% | 0% | – | – | – | |
| PHIOPhio Pharmaceuticals Corp. | $9.3M | +0.2% | -100.0% | 0% | – | – | – | |
| LSTALisata Therapeutics, Inc. | $9.3M | +3.9% | -0.0% | 95% | – | – | – | |
| INABIN8bio, Inc. | $9.1M | +11.6% | +418.5% | 0% | – | – | – | |
| 同行中位数 | – | – | -0.0% | 4.5% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 SGD（非美元）暂无季度数据（首次研究运行后填充）。